by BERNAMA / pic by BLOOMBERG
WASHINGTON – The US pharmaceutical and medical device company Johnson and Johnson has developed a vaccine that in the early trials showed a strong immune response to the novel coronavirus with a single dose, according to Sputnik News Agency quoting an interim report published on the medical website medRxiv.
“The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5×1010 vp, as a potentially protective vaccine against COVID-19,”said the report.
“A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients.”
The Johnson and Johnson vaccine is the fourth in the United States to enter the final phase of clinical trials.
President Donald Trump has promised that 100 million doses of a vaccine will be distributed throughout the United States by the end of the year. Trump said a vaccine could be available for distribution before the presidential election on Nov 3.